Sanofi Long Term Debt 2012-2026 | SNY
Sanofi long term debt from 2012 to 2026. Long term debt can be defined as the sum of all long term debt fields.
- Sanofi long term debt for the quarter ending March 31, 2026 was $14.394B, a 16.11% increase year-over-year.
- Sanofi long term debt for 2024 was $12.759B, a 17.83% decline from 2023.
- Sanofi long term debt for 2023 was $15.528B, a 0.8% decline from 2022.
- Sanofi long term debt for 2022 was $15.653B, a 22.73% decline from 2021.
|
Sanofi Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $12,759 |
| 2023 | $15,528 |
| 2022 | $15,653 |
| 2021 | $20,258 |
| 2020 | $22,555 |
| 2019 | $22,547 |
| 2018 | $25,990 |
| 2017 | $16,193 |
| 2016 | $18,607 |
| 2015 | $14,566 |
| 2014 | $17,648 |
| 2013 | $13,833 |
| 2012 | $13,786 |
| 2011 | $17,409 |
|
Sanofi Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2026-03-31 | $14,394 |
| 2025-12-31 | $16,120 |
| 2025-09-30 | $13,676 |
| 2025-06-30 | $14,985 |
| 2025-03-31 | $12,397 |
| 2024-12-31 | $12,759 |
| 2024-09-30 | |
| 2024-06-30 | $13,464 |
| 2024-03-31 | |
| 2023-12-31 | $15,528 |
| 2023-09-30 | |
| 2023-06-30 | $15,528 |
| 2023-03-31 | |
| 2022-12-31 | $15,653 |
| 2022-09-30 | |
| 2022-06-30 | $16,965 |
| 2022-03-31 | |
| 2021-09-30 | |
| 2021-03-31 | |
| 2020-09-30 | |
| 2020-03-31 | |
| 2019-09-30 | |
| 2019-03-31 | |
| 2018-03-31 | |
| 2017-12-31 | $16,193 |
| 2017-09-30 | |
| 2017-06-30 | $16,708 |
| 2017-03-31 | |
| 2016-12-31 | $18,607 |
| 2016-09-30 | |
| 2016-06-30 | $16,775 |
| 2016-03-31 | |
| 2015-09-30 | |
| 2015-06-30 | $11,914 |
| 2014-06-30 | $13,873 |
| 2013-06-30 | $13,959 |
| 2012-06-30 | $13,198 |
| 2012-03-31 | |
| 2011-12-31 | $17,409 |
| 2011-09-30 | |
| 2011-06-30 | $19,122 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |